EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 3.0

Spotlight on dinutuximab in the treatment of high-risk neuroblastoma: development and place in therapy

Michelle E Keyel, C Patrick Reynolds

Biologics: Targets and Therapy · 2018-12 · Volume 13 · 1-12

DOI: 10.2147/btt.s114530 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Biologics: Targets and Therapy, 2018-12. Verfasst von Michelle E Keyel und 1 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Center, Patrick.Reynolds@ttuhsc.edu. Die Arbeit wurde bisher 32-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

GD2immunotherapymonoclonal antibodyneuroblastoma

Autor:innen und Institutionen

  • Cancer Center, Patrick.Reynolds@ttuhsc.edu.
  • Department of Pediatrics, Patrick.Reynolds@ttuhsc.edu.
  • Department of Internal Medicine, Patrick.Reynolds@ttuhsc.edu.
  • Department of Cell Biology & Biochemistry, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX, USA, Patrick.Reynolds@ttuhsc.edu.

Zitieren

APA

Keyel, M. E., & Reynolds, C. P. (2018). Spotlight on dinutuximab in the treatment of high-risk neuroblastoma: development and place in therapy. Biologics: Targets and Therapy, Volume 13, 1-12. https://doi.org/10.2147/btt.s114530

Vancouver

Keyel ME, Reynolds CP. Spotlight on dinutuximab in the treatment of high-risk neuroblastoma: development and place in therapy. Biologics: Targets and Therapy. 2018;Volume 13:1-12. doi:10.2147/btt.s114530

BibTeX
@article{Keyel2018,
  author = {Keyel, Michelle E and Reynolds, C Patrick},
  title = {Spotlight on dinutuximab in the treatment of high-risk neuroblastoma: development and place in therapy},
  journal = {Biologics: Targets and Therapy},
  year = {2018},
  volume = {Volume 13},
  pages = {1--12},
  doi = {10.2147/btt.s114530}
}
Kostenlos starten →